ClinicalTrials.gov
public full text
Public Domain
A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease
The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease (AD) dementia. This is done by looking at participants: thinking and memory (cognition), everyday activities and sleep, AD symptoms, physical activity, irritability or anxiety. The study is expected to last approximately 26 weeks and may include up to 14 visits.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)#1111949
- Effects of Modafinil, Caffeine and Methylphenidate in Healthy Volunteers#858624
- Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance#838510
- Radiomics-enhanced (18)F-AV45 PET/MRI for integrative assessment and centiloid estimation of amyloid-β burden in Alzheimer's disease.#297124
- Modafinil for Treatment of Fatigue in ALS Patients#1008003
Record · ID 1045580
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive